{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:27Z","timestamp":1793339187831,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00125-025-06653-7","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:11:56Z","timestamp":1769447516000},"page":"855-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review"],"prefix":"10.1007","volume":"69","author":[{"given":"Heather","family":"Sharpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"21","key":"6653_CR1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/JAMA.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW (2023) Cystic fibrosis: a review. JAMA 329(21):1859\u20131871. https:\/\/doi.org\/10.1001\/JAMA.2023.8120","journal-title":"JAMA"},{"issue":"6","key":"6653_CR2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1210\/CLINEM\/DGAC020","volume":"107","author":"A Moheet","year":"2022","unstructured":"Moheet A, Moran A (2022) New concepts in the pathogenesis of cystic fibrosis-related diabetes. J Clin Endocrinol Metab 107(6):1503\u20131509. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC020","journal-title":"J Clin Endocrinol Metab"},{"key":"6653_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/J.PRRV.2022.11.005","volume":"46","author":"B Prentice","year":"2023","unstructured":"Prentice B, Nicholson M, Lam GY (2023) Cystic fibrosis related diabetes (CFRD) in the era of modulators: a scoping review. Paediatr Respir Rev 46:23\u201329. https:\/\/doi.org\/10.1016\/J.PRRV.2022.11.005","journal-title":"Paediatr Respir Rev"},{"issue":"159","key":"6653_CR4","doi-asserted-by":"publisher","first-page":"200293","DOI":"10.1183\/16000617.0293-2020","volume":"30","author":"BJ Prentice","year":"2021","unstructured":"Prentice BJ, Jaffe A, Hameed S et al (2021) Cystic fibrosis-related diabetes and lung disease: an update. Eur Respir Rev 30(159):200293. https:\/\/doi.org\/10.1183\/16000617.0293-2020","journal-title":"Eur Respir Rev"},{"issue":"1","key":"6653_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/J.JCJD.2024.09.001","volume":"49","author":"A Coriati","year":"2025","unstructured":"Coriati A, Potter KJ, Gilmour J et al (2025) Cystic fibrosis\u2013related diabetes: a first Canadian clinical practice guideline. Can J Diabetes 49(1):19-28.e16. https:\/\/doi.org\/10.1016\/J.JCJD.2024.09.001","journal-title":"Can J Diabetes"},{"issue":"9","key":"6653_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/DC09-0586","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32(9):1626\u20131631. https:\/\/doi.org\/10.2337\/DC09-0586","journal-title":"Diabetes Care"},{"issue":"11","key":"6653_CR7","doi-asserted-by":"publisher","first-page":"102899","DOI":"10.1016\/J.DSX.2023.102899","volume":"17","author":"F Lurquin","year":"2023","unstructured":"Lurquin F, Buysschaert M, Preumont V (2023) Advances in cystic fibrosis-related diabetes: current status and future directions. Diabetes Metab Syndr Clin Res Rev 17(11):102899. https:\/\/doi.org\/10.1016\/J.DSX.2023.102899","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"3","key":"6653_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/DIAGNOSTICS11030572","volume":"11","author":"F Iafusco","year":"2021","unstructured":"Iafusco F, Maione G, Rosanio FM, Mozzillo E, Franzese A, Tinto N (2021) Cystic Fibrosis-Related Diabetes (CFRD): overview of associated genetic factors. Diagnostics 11(3):572. https:\/\/doi.org\/10.3390\/DIAGNOSTICS11030572","journal-title":"Diagnostics"},{"key":"6653_CR9","doi-asserted-by":"publisher","first-page":"702823","DOI":"10.3389\/FENDO.2021.702823\/PDF","volume":"12","author":"L Coderre","year":"2021","unstructured":"Coderre L, Debieche L, Plourde J, Rabasa-Lhoret R, Lesage S (2021) The potential causes of cystic fibrosis-related diabetes. Front Endocrinol (Lausanne) 12:702823. https:\/\/doi.org\/10.3389\/FENDO.2021.702823\/PDF","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6653_CR10","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/J.JCTE.2021.100290","volume":"27","author":"S Khare","year":"2022","unstructured":"Khare S, Desimone M, Kasim N, Chan CL (2022) Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis. J Clin Transl Endocrinol 27:100290. https:\/\/doi.org\/10.1016\/J.JCTE.2021.100290","journal-title":"J Clin Transl Endocrinol"},{"issue":"Suppl 1","key":"6653_CR11","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association (2025) Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care 48(Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"issue":"8","key":"6653_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/PEDI.13453","volume":"23","author":"KL Ode","year":"2022","unstructured":"Ode KL, Ballman M, Battezzati A et al (2022) ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 23(8):1212\u20131228. https:\/\/doi.org\/10.1111\/PEDI.13453","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"6653_CR13","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/DC10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33(12):2697\u20132708. https:\/\/doi.org\/10.2337\/DC10-1768","journal-title":"Diabetes Care"},{"key":"6653_CR14","doi-asserted-by":"publisher","first-page":"100279","DOI":"10.1016\/j.jcte.2021.100279","volume":"26","author":"KA Mason","year":"2021","unstructured":"Mason KA, Mark BE, Wood CL, Le TN (2021) Cystic fibrosis-related diabetes: the patient perspective. J Clin Transl Endocrinol 26:100279. https:\/\/doi.org\/10.1016\/j.jcte.2021.100279","journal-title":"J Clin Transl Endocrinol"},{"key":"6653_CR15","doi-asserted-by":"publisher","first-page":"1183288","DOI":"10.3389\/fendo.2023.1183288","volume":"14","author":"R Hicks","year":"2023","unstructured":"Hicks R, Ode KL, Vigers T, Chan CL (2023) A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers. Front Endocrinol (Lausanne) 14:1183288. https:\/\/doi.org\/10.3389\/fendo.2023.1183288","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6653_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/J.JCF.2017.05.010","volume":"17","author":"GY Lam","year":"2018","unstructured":"Lam GY, Doll-Shankaruk M, Dayton J et al (2018) The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening. J Cyst Fibros 17(1):121\u2013124. https:\/\/doi.org\/10.1016\/J.JCF.2017.05.010","journal-title":"J Cyst Fibros"},{"issue":"8","key":"6653_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/PEDI.12914","volume":"20","author":"KL Tommerdahl","year":"2019","unstructured":"Tommerdahl KL, Brinton JT, Vigers T, Nadeau KJ, Zeitler PS, Chan CL (2019) Screening for cystic fibrosis-related diabetes and prediabetes: evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c. Pediatr Diabetes 20(8):1080\u20131086. https:\/\/doi.org\/10.1111\/PEDI.12914","journal-title":"Pediatr Diabetes"},{"issue":"6 Pt 1","key":"6653_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/J.DIABET.2008.05.010","volume":"34","author":"A Godbout","year":"2008","unstructured":"Godbout A, Hammana I, Potvin S et al (2008) No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 34(6 Pt 1):568\u2013573. https:\/\/doi.org\/10.1016\/J.DIABET.2008.05.010","journal-title":"Diabetes Metab"},{"issue":"3","key":"6653_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/S00592-015-0791-3","volume":"53","author":"A Coriati","year":"2016","unstructured":"Coriati A, Ziai S, Lavoie A, Berthiaume Y, Rabasa-Lhoret R (2016) The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis. Acta Diabetol 53(3):359\u2013366. https:\/\/doi.org\/10.1007\/S00592-015-0791-3","journal-title":"Acta Diabetol"},{"issue":"2","key":"6653_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4158\/EP09149.OR","volume":"16","author":"KEH Kinnaird","year":"2010","unstructured":"Kinnaird KEH, Sauerwein TJ (2010) Lack of correlation between 1,5-anhydro glucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocr Pract 16(2):167\u2013170. https:\/\/doi.org\/10.4158\/EP09149.OR","journal-title":"Endocr Pract"},{"issue":"8","key":"6653_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1515\/JPEM-2017-0122\/MACHINEREADABLECITATION\/RIS","volume":"30","author":"V Boudreau","year":"2017","unstructured":"Boudreau V, Lehoux Dubois C, Desjardins K, Mailhot M, Tremblay F, Rabasa-Lhoret R (2017) Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method? J Pediatr Endocrinol Metab 30(8):885\u2013887. https:\/\/doi.org\/10.1515\/JPEM-2017-0122\/MACHINEREADABLECITATION\/RIS","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"6653_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1515\/JPEM-2016-0184","volume":"30","author":"C Mainguy","year":"2017","unstructured":"Mainguy C, Bellon G, Delaup V et al (2017) Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard? J Pediatr Endocrinol Metab 30(1):27\u201335. https:\/\/doi.org\/10.1515\/JPEM-2016-0184","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"6653_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/J.JCF.2021.05.010","volume":"21","author":"T Toin","year":"2022","unstructured":"Toin T, Reynaud Q, Denis A et al (2022) HOMA indices as screening tests for cystic fibrosis-related diabetes. J Cyst Fibros 21(1):123\u2013128. https:\/\/doi.org\/10.1016\/J.JCF.2021.05.010","journal-title":"J Cyst Fibros"},{"issue":"4","key":"6653_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0889-8529(05)70102-X","volume":"28","author":"DS Hardin","year":"1999","unstructured":"Hardin DS, Moran A (1999) Diabetes mellitus in cystic fibrosis. Endocrinol Metab Clin North Am 28(4):787\u2013800. https:\/\/doi.org\/10.1016\/S0889-8529(05)70102-X","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"6653_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.JCJD.2018.04.008","volume":"43","author":"JA Gilmour","year":"2019","unstructured":"Gilmour JA, Sykes J, Etchells E, Tullis E (2019) Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels. Can J Diabetes 43(1):13\u201318. https:\/\/doi.org\/10.1016\/J.JCJD.2018.04.008","journal-title":"Can J Diabetes"},{"key":"6653_CR26","doi-asserted-by":"publisher","first-page":"111124","DOI":"10.1016\/j.diabres.2024.111124","volume":"208","author":"F Lurquin","year":"2024","unstructured":"Lurquin F, Gohy S, Hermans MP, Preumont V (2024) Novel time-saving OGTT sparing HbA1c-HOMA2 based algorithm for the diagnosis of cystic fibrosis-related diabetes. Diabetes Res Clin Pract 208:111124. https:\/\/doi.org\/10.1016\/j.diabres.2024.111124","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"6653_CR27","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/S00125-024-06223-3\/METRICS","volume":"67","author":"KJ Scully","year":"2024","unstructured":"Scully KJ, Marks BE, Putman MS (2024) Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia 67(10):2143\u20132153. https:\/\/doi.org\/10.1007\/S00125-024-06223-3\/METRICS","journal-title":"Diabetologia"},{"issue":"6","key":"6653_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","volume":"17","author":"CL Chan","year":"2018","unstructured":"Chan CL, Vigers T, Pyle L, Zeitler PS, Sagel SD, Nadeau KJ (2018) Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibros 17(6):783\u2013790. https:\/\/doi.org\/10.1016\/j.jcf.2018.03.008","journal-title":"J Cyst Fibros"},{"issue":"4","key":"6653_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","volume":"13","author":"A Leclercq","year":"2014","unstructured":"Leclercq A, Gauthier B, Rosner V et al (2014) Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros 13(4):478\u2013484. https:\/\/doi.org\/10.1016\/j.jcf.2013.11.005","journal-title":"J Cyst Fibros"},{"issue":"5","key":"6653_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/J.JCF.2021.03.004","volume":"20","author":"M Pallin","year":"2021","unstructured":"Pallin M, Kumar S, Daley C et al (2021) Continuous glucose monitoring indices predict poor FEV1 recovery following cystic fibrosis pulmonary exacerbations. J Cyst Fibros 20(5):785\u2013791. https:\/\/doi.org\/10.1016\/J.JCF.2021.03.004","journal-title":"J Cyst Fibros"},{"issue":"2","key":"6653_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2337\/DC09-1492","volume":"33","author":"S Hameed","year":"2010","unstructured":"Hameed S, Morton JR, Jaff\u00e9 A et al (2010) Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33(2):221\u2013226. https:\/\/doi.org\/10.2337\/DC09-1492","journal-title":"Diabetes Care"},{"issue":"6","key":"6653_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/biomedicines11061754","volume":"11","author":"F Sebastian-Valles","year":"2023","unstructured":"Sebastian-Valles F, Arranz Mart\u00edn JA, Gir\u00f3n RM et al (2023) Continuous glucose monitoring as an additional tool in early cystic fibrosis-related diabetes monitoring and in evaluation of short-term sitagliptin response. Biomedicines 11(6):1754. https:\/\/doi.org\/10.3390\/biomedicines11061754","journal-title":"Biomedicines"},{"key":"6653_CR33","doi-asserted-by":"publisher","first-page":"659728","DOI":"10.3389\/fped.2021.659728","volume":"9","author":"B Gojsina","year":"2021","unstructured":"Gojsina B, Minic P, Todorovic S, Soldatovic I, Sovtic A (2021) Continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis. Front Pediatr 9:659728. https:\/\/doi.org\/10.3389\/fped.2021.659728","journal-title":"Front Pediatr"},{"issue":"4","key":"6653_CR34","doi-asserted-by":"publisher","first-page":"108703","DOI":"10.1016\/J.JDIACOMP.2024.108703","volume":"38","author":"L Rakotoarisoa","year":"2024","unstructured":"Rakotoarisoa L, Weiss L, Lefebvre F et al (2024) Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: a five-year prospective study. J Diabetes Complications 38(4):108703. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2024.108703","journal-title":"J Diabetes Complications"},{"key":"6653_CR35","doi-asserted-by":"publisher","first-page":"1293709","DOI":"10.3389\/FENDO.2024.1293709\/BIBTEX","volume":"15","author":"KJ Scully","year":"2024","unstructured":"Scully KJ, Brenner L, Martin K et al (2024) Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne) 15:1293709. https:\/\/doi.org\/10.3389\/FENDO.2024.1293709\/BIBTEX","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6653_CR36","doi-asserted-by":"publisher","first-page":"e20210307","DOI":"10.36416\/1806-3756\/e20210307","volume":"48","author":"M Zorron","year":"2022","unstructured":"Zorron M, Marson FAL, Morcillo AM et al (2022) Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome? J Bras Pneumol 48(2):e20210307. https:\/\/doi.org\/10.36416\/1806-3756\/e20210307","journal-title":"J Bras Pneumol"},{"key":"6653_CR37","doi-asserted-by":"publisher","first-page":"1527932","DOI":"10.1155\/2016\/1527932","volume":"2016","author":"JL Taylor-Cousar","year":"2016","unstructured":"Taylor-Cousar JL, Janssen JS, Wilson A et al (2016) Glucose >200 mg\/dL during continuous glucose monitoring identifies adult patients at risk for development of cystic fibrosis related diabetes. J Diabetes Res 2016:1527932. https:\/\/doi.org\/10.1155\/2016\/1527932","journal-title":"J Diabetes Res"},{"issue":"4","key":"6653_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/EJE-09-1020","volume":"162","author":"R Schiaffini","year":"2010","unstructured":"Schiaffini R, Brufani C, Russo B et al (2010) Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. Eur J Endocrinol 162(4):705\u2013710. https:\/\/doi.org\/10.1530\/EJE-09-1020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"6653_CR39","doi-asserted-by":"publisher","first-page":"e1444","DOI":"10.1210\/CLINEM\/DGAB857","volume":"107","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Sherwood JS, Martin K et al (2022) Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab 107(4):e1444\u2013e1454. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB857","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6653_CR40","doi-asserted-by":"publisher","first-page":"E548","DOI":"10.1210\/CLINEM\/DGAB692","volume":"107","author":"CL Chan","year":"2022","unstructured":"Chan CL, Pyle L, Vigers T, Zeitler PS, Nadeau KJ (2022) The relationship between continuous glucose monitoring and OGTT in youth and young adults with cystic fibrosis. J Clin Endocrinol Metab 107(2):E548\u2013E560. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB692","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6653_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jcf.2023.01.016","volume":"22","author":"DS Hameed","year":"2023","unstructured":"Hameed DS (2023) Early Glucose abnormalities in cystic fibrosis \u2013 how best to measure them, and what is to be done about them? J Cyst Fibros 22(1):3\u20134. https:\/\/doi.org\/10.1016\/j.jcf.2023.01.016","journal-title":"J Cyst Fibros"},{"issue":"12","key":"6653_CR42","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.2337\/DC10-0613","volume":"33","author":"BI Frohnert","year":"2010","unstructured":"Frohnert BI, Ode KL, Moran A et al (2010) Impaired fasting glucose in cystic fibrosis. Diabetes Care 33(12):2660. https:\/\/doi.org\/10.2337\/DC10-0613","journal-title":"Diabetes Care"},{"issue":"1","key":"6653_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jcf.2013.06.001","volume":"13","author":"K Schmid","year":"2014","unstructured":"Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M (2014) Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros 13(1):80\u201385. https:\/\/doi.org\/10.1016\/j.jcf.2013.06.001","journal-title":"J Cyst Fibros"},{"key":"6653_CR44","doi-asserted-by":"publisher","first-page":"1269139","DOI":"10.3389\/FENDO.2023.1269139","volume":"14","author":"SS Malik","year":"2023","unstructured":"Malik SS, Padmanabhan D, Hull-Meichle RL (2023) Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes. Front Endocrinol (Lausanne) 14:1269139. https:\/\/doi.org\/10.3389\/FENDO.2023.1269139","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"6653_CR45","doi-asserted-by":"publisher","first-page":"E1793","DOI":"10.1210\/CLINEM\/DGAA932","volume":"106","author":"C Piona","year":"2021","unstructured":"Piona C, Volpi S, Zusi C et al (2021) Glucose tolerance stages in cystic fibrosis are identified by a unique pattern of defects of beta-cell function. J Clin Endocrinol Metab 106(4):E1793\u2013E1802. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA932","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6653_CR46","doi-asserted-by":"publisher","first-page":"E851","DOI":"10.1210\/jc.2010-2460","volume":"96","author":"P Kuo","year":"2011","unstructured":"Kuo P, Stevens JE, Russo A et al (2011) Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis - Effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 96(5):E851\u2013E855. https:\/\/doi.org\/10.1210\/jc.2010-2460","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6653_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/ACTA.0.1280207","volume":"128","author":"S Lanng","year":"1993","unstructured":"Lanng S, Thorsteinsson B, Roder ME et al (1993) Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh) 128(3):207\u2013214. https:\/\/doi.org\/10.1530\/ACTA.0.1280207","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"6653_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","volume":"24","author":"M Destoop","year":"2025","unstructured":"Destoop M, Brantner C, Wilms EB et al (2025) CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case. J Cyst Fibros 24(3):476\u2013478. https:\/\/doi.org\/10.1016\/j.jcf.2025.03.006","journal-title":"J Cyst Fibros"},{"issue":"3","key":"6653_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","volume":"24","author":"A Metcalf","year":"2025","unstructured":"Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE (2025) Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros 24(3):466\u2013468. https:\/\/doi.org\/10.1016\/j.jcf.2024.11.011","journal-title":"J Cyst Fibros"},{"issue":"5","key":"6653_CR50","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","volume":"23","author":"A Kowalik","year":"2024","unstructured":"Kowalik A, Roberts E, Harris AH et al (2024) Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies. J Cyst Fibros 23(5):1027\u20131030. https:\/\/doi.org\/10.1016\/j.jcf.2024.06.003","journal-title":"J Cyst Fibros"},{"issue":"suppl 68","key":"6653_CR51","doi-asserted-by":"publisher","first-page":"PA2353","DOI":"10.1183\/13993003.CONGRESS-2024.PA2353","volume":"64","author":"SJ Bourke","year":"2024","unstructured":"Bourke SJ, Duffy A, Williams S et al (2024) Lung health and pregnancy in the cystic fibrosis (CF) modulator era. Eur Respir J 64(suppl 68):PA2353. https:\/\/doi.org\/10.1183\/13993003.CONGRESS-2024.PA2353","journal-title":"Eur Respir J"},{"key":"6653_CR52","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/s1569-1993(24)00151-6","volume":"23","author":"C Etherington","year":"2024","unstructured":"Etherington C, Shimmin D, Clifton I, Spoletini G, Peckham D (2024) WS07.06 Maternal and foetal outcomes following elexacaftor\/tezacaftor\/ivacaftor (ETI) use during pregnancy: comparison with pregnancy outcome data from the pre modulator era. J Cyst Fibros 23:S14. https:\/\/doi.org\/10.1016\/s1569-1993(24)00151-6","journal-title":"J Cyst Fibros"},{"issue":"10","key":"6653_CR53","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1007\/S00125-020-05210-8\/TABLES\/1","volume":"63","author":"MR Rickels","year":"2020","unstructured":"Rickels MR, Norris AW, Hull RL (2020) A tale of two pancreases: exocrine pathology and endocrine dysfunction. Diabetologia 63(10):2030\u20132039. https:\/\/doi.org\/10.1007\/S00125-020-05210-8\/TABLES\/1","journal-title":"Diabetologia"},{"key":"6653_CR54","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/J.JCF.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R (2019) Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. J Cyst Fibros 18:S3\u2013S9. https:\/\/doi.org\/10.1016\/J.JCF.2019.08.016","journal-title":"J Cyst Fibros"},{"issue":"5","key":"6653_CR55","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2337\/DC06-1576","volume":"30","author":"SJ Schwarzenberg","year":"2007","unstructured":"Schwarzenberg SJ, Thomas W, Olsen TW et al (2007) Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 30(5):1056\u20131061. https:\/\/doi.org\/10.2337\/DC06-1576","journal-title":"Diabetes Care"},{"issue":"3","key":"6653_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/J.JCF.2021.04.014","volume":"21","author":"HK Chadwick","year":"2022","unstructured":"Chadwick HK, Abbott J, Hurley MA et al (2022) Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis. J Cyst Fibros 21(3):519\u2013528. https:\/\/doi.org\/10.1016\/J.JCF.2021.04.014","journal-title":"J Cyst Fibros"},{"issue":"7","key":"6653_CR57","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/02713683.2024.2333770","volume":"49","author":"LS Saegebrecht","year":"2024","unstructured":"Saegebrecht LS, R\u00f6hlig M, Schaub F, Ballmann M, Stachs O, Fischer DC (2024) Glycemic variability and the thickness of retinal layers in cystic fibrosis patients with and without cystic fibrosis related diabetes. Curr Eye Res 49(7):759\u2013767. https:\/\/doi.org\/10.1080\/02713683.2024.2333770","journal-title":"Curr Eye Res"},{"issue":"2","key":"6653_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/J.JCF.2023.01.010","volume":"22","author":"LR Caley","year":"2023","unstructured":"Caley LR, Zagoya C, Duckstein F et al (2023) Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis. J Cyst Fibros 22(2):275\u2013281. https:\/\/doi.org\/10.1016\/J.JCF.2023.01.010","journal-title":"J Cyst Fibros"},{"key":"6653_CR59","doi-asserted-by":"publisher","first-page":"117955142110382","DOI":"10.1177\/11795514211038259","volume":"14","author":"BU Nielsen","year":"2021","unstructured":"Nielsen BU, Faurholt-Jepsen D, Oturai PS et al (2021) Associations between glucose tolerance, insulin secretion, muscle and fat mass in cystic fibrosis. Clin Med Insights Endocrinol Diabetes 14:11795514211038260. https:\/\/doi.org\/10.1177\/11795514211038259","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"6653_CR60","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/J.JCTE.2021.100278","volume":"26","author":"Z Sandouk","year":"2021","unstructured":"Sandouk Z, Khan F, Khare S, Moran A (2021) Cystic fibrosis related diabetes (CFRD) prognosis. J Clin Transl Endocrinol 26:100278. https:\/\/doi.org\/10.1016\/J.JCTE.2021.100278","journal-title":"J Clin Transl Endocrinol"},{"issue":"3","key":"6653_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1203\/00006450-199809000-00240","volume":"44","author":"DC Wilson","year":"1998","unstructured":"Wilson DC, Solomon M, Hanna AK et al (1998) Long-term microvascular, but not macrovascular, diabetic complications are common in cystic fibrosis related diabetes mellitus. Pediatr Res 44(3):453. https:\/\/doi.org\/10.1203\/00006450-199809000-00240","journal-title":"Pediatr Res"},{"key":"6653_CR62","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/J.JCTE.2022.100308","volume":"30","author":"Z Sandouk","year":"2022","unstructured":"Sandouk Z, Nachawi N, Simon R et al (2022) Coronary artery disease in patients with cystic fibrosis \u2013 A case series and review of the literature. J Clin Transl Endocrinol 30:100308. https:\/\/doi.org\/10.1016\/J.JCTE.2022.100308","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"6653_CR63","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/J.JCF.2021.11.013","volume":"21","author":"SR Thambuluru","year":"2022","unstructured":"Thambuluru SR, Kyazimzade S, Despotes KA, Kirk D, Goralski JL (2022) Acute ST-elevation myocardial infarction in two young women with cystic fibrosis and cystic fibrosis-related diabetes. J Cyst Fibros 21(1):e44\u2013e47. https:\/\/doi.org\/10.1016\/J.JCF.2021.11.013","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcf.2021.04.016","volume":"21","author":"TS Poore","year":"2022","unstructured":"Poore TS, Taylor-Cousar JL, Zemanick ET (2022) Cardiovascular complications in cystic fibrosis: a review of the literature. J Cyst Fibros 21(1):18\u201325. https:\/\/doi.org\/10.1016\/j.jcf.2021.04.016","journal-title":"J Cyst Fibros"},{"issue":"4","key":"6653_CR65","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL (2023) Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros 22(4):607\u2013614. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12931-023-02451-0\/FIGURES\/4","volume":"24","author":"A Gramegna","year":"2023","unstructured":"Gramegna A, Majo F, Alicandro G et al (2023) Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis. Respir Res 24(1):1\u20137. https:\/\/doi.org\/10.1186\/S12931-023-02451-0\/FIGURES\/4","journal-title":"Respir Res"},{"issue":"6","key":"6653_CR67","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/PPUL.26982","volume":"59","author":"KL Stewart","year":"2024","unstructured":"Stewart KL, Szczesniak R, Liou TG (2024) Predicting weight gain in patients with Cystic Fibrosis on triple combination modulator. Pediatr Pulmonol 59(6):1724. https:\/\/doi.org\/10.1002\/PPUL.26982","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"6653_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/RESP.12227","volume":"19","author":"PG Middleton","year":"2014","unstructured":"Middleton PG, Wagenaar M, Matson AG et al (2014) Australian standards of care for cystic fibrosis-related diabetes. Respirology 19(2):185\u2013192. https:\/\/doi.org\/10.1111\/RESP.12227","journal-title":"Respirology"},{"issue":"10","key":"6653_CR69","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5694\/MJA2.52119","volume":"219","author":"S Kumar","year":"2023","unstructured":"Kumar S, Soldatos G, Teede HJ, Pallin M (2023) Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review. Med J Aust 219(10):496\u2013502. https:\/\/doi.org\/10.5694\/MJA2.52119","journal-title":"Med J Aust"},{"issue":"2","key":"6653_CR70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","volume":"6","author":"M Ballmann","year":"2018","unstructured":"Ballmann M, Hubert D, Assael BM et al (2018) Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(2):114\u2013121. https:\/\/doi.org\/10.1016\/S2213-8587(17)30400-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6653_CR71","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2337\/DC09-0585","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Pekow P, Grover P et al (2009) Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 32(10):1783\u20131788. https:\/\/doi.org\/10.2337\/DC09-0585","journal-title":"Diabetes Care"},{"issue":"3","key":"6653_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/J.JCJD.2023.02.002","volume":"47","author":"KJ Potter","year":"2023","unstructured":"Potter KJ, Coriati A, Hicks P et al (2023) Canadian cystic fibrosis\u2013related diabetes clinical practice survey: analysis of current practices and gaps in clinical care. Can J Diabetes 47(3):263-271.e1. https:\/\/doi.org\/10.1016\/J.JCJD.2023.02.002","journal-title":"Can J Diabetes"},{"issue":"2","key":"6653_CR73","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/J.JCJD.2024.12.003","volume":"49","author":"M Gerges","year":"2025","unstructured":"Gerges M, Chiasson M, Nichols C, Morrison N, De B (2025) Possible drug interaction between elexacaftor-tezacaftor-ivacaftor and repaglinide in an adult with cystic fibrosis\u2013related diabetes. Can J Diabetes 49(2):136\u2013137. https:\/\/doi.org\/10.1016\/J.JCJD.2024.12.003","journal-title":"Can J Diabetes"},{"issue":"5","key":"6653_CR74","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/J.JCF.2024.06.007","volume":"23","author":"A Santhakumar","year":"2024","unstructured":"Santhakumar A, Lewis F, Pickles J et al (2024) Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: a single centre experience. J Cyst Fibros 23(5):853\u2013856. https:\/\/doi.org\/10.1016\/J.JCF.2024.06.007","journal-title":"J Cyst Fibros"},{"key":"6653_CR75","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/J.JCF.2025.03.1177","volume":"24","author":"B Yusuf","year":"2025","unstructured":"Yusuf B, Spoletini G, Shimmin D, Pearson S, Peckham D (2025) P291 A large single CF centre experience of DPP4 inhibitors in cystic fibrosis diabetes. J Cyst Fibros 24:S159. https:\/\/doi.org\/10.1016\/J.JCF.2025.03.1177","journal-title":"J Cyst Fibros"},{"issue":"6","key":"6653_CR76","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/J.JCF.2021.02.005","volume":"20","author":"ST Olatunbosun","year":"2021","unstructured":"Olatunbosun ST (2021) Chronic incretin-based therapy in cystic fibrosis-related diabetes: a tale of 3 patients treated with sitagliptin for over 5 years. J Cyst Fibros 20(6):e124\u2013e128. https:\/\/doi.org\/10.1016\/J.JCF.2021.02.005","journal-title":"J Cyst Fibros"},{"issue":"9","key":"6653_CR77","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1210\/CLINEM\/DGAB365","volume":"106","author":"A Kelly","year":"2021","unstructured":"Kelly A, Sheikh S, Stefanovski D et al (2021) Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance. J Clin Endocrinol Metab 106(9):2617\u20132634. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB365","journal-title":"J Clin Endocrinol Metab"},{"key":"6653_CR78","doi-asserted-by":"publisher","unstructured":"Richstein R, Menon T, Wang J. Cystic fibrosis-related diabetes. Contemp Endocrinol 2023 Part F2156:217\u2013234. https:\/\/doi.org\/10.1007\/978-3-031-44648-1_16\/TABLES\/3","DOI":"10.1007\/978-3-031-44648-1_16\/TABLES\/3"},{"key":"6653_CR79","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/J.JCF.2025.03.1176","volume":"24","author":"P Dyce","year":"2025","unstructured":"Dyce P, Jackson V, Walshaw M, White R, Ochota A, Foster K (2025) P290 From insulin to oral medication in mild CFD - time to switch? J Cyst Fibros 24:S159. https:\/\/doi.org\/10.1016\/J.JCF.2025.03.1176","journal-title":"J Cyst Fibros"},{"issue":"Suppl 4","key":"6653_CR80","doi-asserted-by":"publisher","first-page":"A172","DOI":"10.1136\/THORAX-2023-BTSABSTRACTS.262","volume":"78","author":"A Salih","year":"2023","unstructured":"Salih A, Islam I, Wills H et al (2023) P110 Metformin in patients with cystic fibrosis-related diabetes (CFRD): outcomes from a single UK centre. Thorax 78(Suppl 4):A172\u2013A172. https:\/\/doi.org\/10.1136\/THORAX-2023-BTSABSTRACTS.262","journal-title":"Thorax"},{"key":"6653_CR81","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/s1569-1993(24)00591-5","volume":"23","author":"C Dewdney","year":"2024","unstructured":"Dewdney C, Robb L, Arunagirinathan G, Ritchie S (2024) P290 Could metformin be a viable treatment option for patients with cystic fibrosis diabetes? J Cyst Fibros 23:S158. https:\/\/doi.org\/10.1016\/s1569-1993(24)00591-5","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.JCF.2024.08.005","volume":"24","author":"S Park","year":"2025","unstructured":"Park S, Jain R, Mirfakhraee S (2025) Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. J Cyst Fibros 24(1):40\u201346. https:\/\/doi.org\/10.1016\/J.JCF.2024.08.005","journal-title":"J Cyst Fibros"},{"key":"6653_CR83","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/J.JCTE.2024.100375","volume":"38","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Ankireddypalli A, Harindhanavudhi T, Moran A, Moheet A (2024) Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review. J Clin Transl Endocrinol 38:100375. https:\/\/doi.org\/10.1016\/J.JCTE.2024.100375","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"6653_CR84","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/dia.2024.0367","volume":"27","author":"G Ayada","year":"2025","unstructured":"Ayada G, Zolotov S, Cohen R et al (2025) GLP-1 receptor agonist therapy in cystic fibrosis-related diabetes: a case report. Diabetes Technol Ther 27(2):144\u2013146. https:\/\/doi.org\/10.1089\/dia.2024.0367","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"6653_CR85","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.aed.2025.03.011","volume":"12","author":"R Auth","year":"2025","unstructured":"Auth R, Dougherty B, Putnam M, Scully K (2025) Glucagon-like peptide 1 agonist use in an adult with cystic fibrosis-related diabetes and metabolic syndrome. AACE Endocrinol Diabetes 12(2):67\u201370. https:\/\/doi.org\/10.1016\/j.aed.2025.03.011","journal-title":"AACE Endocrinol Diabetes"},{"issue":"9","key":"6653_CR86","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/QJMED\/HCAA256","volume":"115","author":"F Frost","year":"2022","unstructured":"Frost F, Walshaw MJ, Nazareth D (2022) Cystic fibrosis-related diabetes: an update. QJM Int J Med 115(9):582\u2013585. https:\/\/doi.org\/10.1093\/QJMED\/HCAA256","journal-title":"QJM Int J Med"},{"issue":"3","key":"6653_CR87","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/S00592-025-02457-8\/FIGURES\/1","volume":"62","author":"I Aguilera Garc\u00eda","year":"2025","unstructured":"Aguilera Garc\u00eda I, Barquiel Alcal\u00e1 B, V\u00e1zquez P\u00e9rez P, Prados S\u00e1nchez MC, de Gonz\u00e1lez P\u00e9rez Villar N (2025) Time to change guidelines? Suboptimal glycemic control measures by CGM associated with cystic fibrosis exacerbations despite adequate HbA1c. Acta Diabetol 62(3):429\u2013431. https:\/\/doi.org\/10.1007\/S00592-025-02457-8\/FIGURES\/1","journal-title":"Acta Diabetol"},{"issue":"5","key":"6653_CR88","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/J.JCF.2023.06.011","volume":"22","author":"L Merjaneh","year":"2023","unstructured":"Merjaneh L, Sidhaye AR, Vu PT et al (2023) Role of hyperglycemia in cystic fibrosis pulmonary exacerbations. J Cyst Fibros 22(5):868. https:\/\/doi.org\/10.1016\/J.JCF.2023.06.011","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcf.2022.07.013","volume":"22","author":"S Kumar","year":"2023","unstructured":"Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M (2023) Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis. J Cyst Fibros 22(1):39\u201349. https:\/\/doi.org\/10.1016\/j.jcf.2022.07.013","journal-title":"J Cyst Fibros"},{"issue":"11","key":"6653_CR90","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/DIA.2021.0201","volume":"23","author":"BE Marks","year":"2021","unstructured":"Marks BE, Kilberg MJ, Aliaj E et al (2021) Perceptions of diabetes technology use in cystic fibrosis-related diabetes management. Diabetes Technol Ther 23(11):753\u2013759. https:\/\/doi.org\/10.1089\/DIA.2021.0201","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6653_CR91","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","volume":"8","author":"DS Hardin","year":"2009","unstructured":"Hardin DS, Rice J, Rice M, Rosenblatt R (2009) Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 8(3):174\u2013178. https:\/\/doi.org\/10.1016\/j.jcf.2008.12.001","journal-title":"J Cyst Fibros"},{"key":"6653_CR92","doi-asserted-by":"publisher","first-page":"1228153","DOI":"10.3389\/FENDO.2023.1228153\/BIBTEX","volume":"14","author":"V Grancini","year":"2023","unstructured":"Grancini V, Alicandro G, Porcaro LL et al (2023) Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes. Front Endocrinol (Lausanne) 14:1228153. https:\/\/doi.org\/10.3389\/FENDO.2023.1228153\/BIBTEX","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"6653_CR93","doi-asserted-by":"publisher","first-page":"A417","DOI":"10.1210\/JENDSO\/BVAE163.797","volume":"8","author":"I Yaseen","year":"2024","unstructured":"Yaseen I, Slattery D (2024) 12567 hybrid closed-loop insulin pumps\u2019 role in CFRD management: a retrospective case series analysis. J Endocr Soc 8(Suppl 1):A417-418. https:\/\/doi.org\/10.1210\/JENDSO\/BVAE163.797","journal-title":"J Endocr Soc"},{"key":"6653_CR94","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/J.JCF.2025.03.1178","volume":"24","author":"B Yusuf","year":"2025","unstructured":"Yusuf B, Spoletini G, Shimmin D, Pearson S, Peckham D (2025) P292 Hybrid closed loop systems in adults with cystic fibrosis diabetes. J Cyst Fibros 24:S159\u2013S160. https:\/\/doi.org\/10.1016\/J.JCF.2025.03.1178","journal-title":"J Cyst Fibros"},{"issue":"11","key":"6653_CR95","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/S00592-024-02329-7","volume":"61","author":"V Grancini","year":"2024","unstructured":"Grancini V, Cogliati I, Gaglio A, Resi V, Orsi E (2024) Offlabel use of Medtronic MiniMed 780G in the management of cystic fibrosis related diabetes in people requiring insulin total daily doses below 8 units: encouraging data from our population. Acta Diabetologica 61(11):1483\u20131489. https:\/\/doi.org\/10.1007\/S00592-024-02329-7","journal-title":"Acta Diabetologica"},{"issue":"6","key":"6653_CR96","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/DIA.2021.0354","volume":"24","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Palani G, Zheng H, Moheet A, Putman MS (2022) The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes. Diabetes Technol Ther 24(6):446\u2013452. https:\/\/doi.org\/10.1089\/DIA.2021.0354","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 1","key":"6653_CR97","doi-asserted-by":"publisher","first-page":"271-OR","DOI":"10.2337\/db24-271-OR","volume":"73","author":"V Grancini","year":"2024","unstructured":"Grancini V, Cogliati I, Gaglio A, Resi V, Orsi E (2024) 271-OR: Automated Hybrid Closed-Loop (AHCL) Systems for the Treatment of Cystic Fibrosis Related Diabetes (CFRD). Diabetes 73(Suppl 1):271-OR. https:\/\/doi.org\/10.2337\/db24-271-OR","journal-title":"Diabetes"},{"key":"6653_CR98","doi-asserted-by":"publisher","first-page":"1347141","DOI":"10.3389\/FENDO.2024.1347141\/BIBTEX","volume":"15","author":"M Bassi","year":"2024","unstructured":"Bassi M, Franzone D, Dufour F et al (2024) Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study. Front Endocrinol (Lausanne) 15:1347141. https:\/\/doi.org\/10.3389\/FENDO.2024.1347141\/BIBTEX","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6653_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2337\/DC23-1411","volume":"47","author":"JS Sherwood","year":"2024","unstructured":"Sherwood JS, Castellanos LE, O\u2019Connor MY et al (2024) Randomized trial of the insulin- only ilet bionic pancreas for the treatment of cystic fibrosis- related diabetes. Diabetes Care 47(1):101\u2013108. https:\/\/doi.org\/10.2337\/DC23-1411","journal-title":"Diabetes Care"},{"issue":"5","key":"6653_CR100","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1210\/EN.2015-1935","volume":"157","author":"Y Yi","year":"2016","unstructured":"Yi Y, Sun X, Gibson-Corley K et al (2016) A transient metabolic recovery from early life glucose intolerance in cystic fibrosis ferrets occurs during pancreatic remodeling. Endocrinology 157(5):1852\u20131865. https:\/\/doi.org\/10.1210\/EN.2015-1935","journal-title":"Endocrinology"},{"issue":"485","key":"6653_CR101","doi-asserted-by":"publisher","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","volume":"11","author":"X Sun","year":"2019","unstructured":"Sun X, Yi Y, Yan Z et al (2019) In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med 11(485):eaau7531. https:\/\/doi.org\/10.1126\/scitranslmed.aau7531","journal-title":"Sci Transl Med"},{"issue":"1","key":"6653_CR102","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/15513818609025923","volume":"6","author":"K Soejima","year":"1986","unstructured":"Soejima K, Landing BH (1986) Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies. Pediatr Pathol 6(1):25\u201346. https:\/\/doi.org\/10.3109\/15513818609025923","journal-title":"Pediatr Pathol"},{"issue":"1","key":"6653_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/NCOMMS5420;TECHMETA","volume":"5","author":"JH Guo","year":"2014","unstructured":"Guo JH, Chen H, Ruan YC et al (2014) Glucose-induced electrical activities and insulin secretion in pancreatic islet 2-cells are modulated by CFTR. Nat Commun 5(1):1\u201310. https:\/\/doi.org\/10.1038\/NCOMMS5420;TECHMETA","journal-title":"Nat Commun"},{"issue":"6","key":"6653_CR104","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2015.02.009","volume":"14","author":"JL Wooldridge","year":"2015","unstructured":"Wooldridge JL, Szczesniak RD, Fenchel MC, Elder DA (2015) Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients. J Cyst Fibros 14(6):792\u2013797. https:\/\/doi.org\/10.1016\/j.jcf.2015.02.009","journal-title":"J Cyst Fibros"},{"key":"6653_CR105","doi-asserted-by":"publisher","first-page":"107664","DOI":"10.1016\/J.RMED.2024.107664","volume":"228","author":"A Cohen","year":"2024","unstructured":"Cohen A, Mass A, Reiter J, Zangen DH, Cohen-Cymberknoh M (2024) Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis. Respir Med 228:107664. https:\/\/doi.org\/10.1016\/J.RMED.2024.107664","journal-title":"Respir Med"},{"issue":"8","key":"6653_CR106","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/THORAXJNL-2017-210394","volume":"73","author":"L Bessonova","year":"2018","unstructured":"Bessonova L, Volkova N, Higgins M et al (2018) Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax 73(8):731\u2013740. https:\/\/doi.org\/10.1136\/THORAXJNL-2017-210394","journal-title":"Thorax"},{"issue":"1","key":"6653_CR107","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","volume":"19","author":"N Volkova","year":"2020","unstructured":"Volkova N, Moy K, Evans J et al (2020) Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros 19(1):68\u201379. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.015","journal-title":"J Cyst Fibros"},{"issue":"3","key":"6653_CR108","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1164\/RCCM.201806-1018OC","volume":"199","author":"A Kelly","year":"2019","unstructured":"Kelly A, De Leon DD, Sheikh S et al (2019) Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy. Am J Respir Crit Care Med 199(3):342\u2013351. https:\/\/doi.org\/10.1164\/RCCM.201806-1018OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"6653_CR109","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","volume":"15","author":"R Tsabari","year":"2016","unstructured":"Tsabari R, Elyashar HI, Cymberknowh MC et al (2016) CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros 15(3):e25\u2013e27. https:\/\/doi.org\/10.1016\/j.jcf.2015.10.012","journal-title":"J Cyst Fibros"},{"issue":"6","key":"6653_CR110","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/PEDI.12026","volume":"14","author":"MD Bellin","year":"2013","unstructured":"Bellin MD, Laguna T, Leschyshyn J et al (2013) Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 14(6):417\u2013421. https:\/\/doi.org\/10.1111\/PEDI.12026","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"6653_CR111","doi-asserted-by":"publisher","first-page":"107845","DOI":"10.1016\/J.JDIACOMP.2020.107845","volume":"35","author":"H Gaines","year":"2021","unstructured":"Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH (2021) Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications 35(6):107845. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2020.107845","journal-title":"J Diabetes Complications"},{"issue":"1","key":"6653_CR112","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcf.2016.09.005","volume":"16","author":"V Mutyam","year":"2017","unstructured":"Mutyam V, Libby EF, Peng N et al (2017) Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros 16(1):24\u201329. https:\/\/doi.org\/10.1016\/j.jcf.2016.09.005","journal-title":"J Cyst Fibros"},{"issue":"5","key":"6653_CR113","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/RCCM.201405-0882LE","volume":"190","author":"D Hayes","year":"2014","unstructured":"Hayes D, McCoy KS, Sheikh SI (2014) Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med 190(5):590\u2013591. https:\/\/doi.org\/10.1164\/RCCM.201405-0882LE","journal-title":"Am J Respir Crit Care Med"},{"key":"6653_CR114","doi-asserted-by":"publisher","first-page":"232470961984289","DOI":"10.1177\/2324709619842898","volume":"7","author":"F Christian","year":"2019","unstructured":"Christian F, Thierman A, Shirley E, Allen K, Cross C, Jones K (2019) Sustained glycemic control with ivacaftor in cystic fibrosis-related diabetes. J Investig Med High Impact Case Rep 7:2324709619842898. https:\/\/doi.org\/10.1177\/2324709619842898","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"5","key":"6653_CR115","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/J.JCF.2020.03.002","volume":"19","author":"B Misgault","year":"2020","unstructured":"Misgault B, Chatron E, Reynaud Q et al (2020) Effect of one-year lumacaftor\u2013ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. J Cyst Fibros 19(5):712\u2013716. https:\/\/doi.org\/10.1016\/J.JCF.2020.03.002","journal-title":"J Cyst Fibros"},{"issue":"2","key":"6653_CR116","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","volume":"20","author":"A Moheet","year":"2021","unstructured":"Moheet A, Beisang D, Zhang L et al (2021) Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients. J Cyst Fibros 20(2):333\u2013338. https:\/\/doi.org\/10.1016\/j.jcf.2020.09.001","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR117","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/J.JCF.2018.07.010","volume":"18","author":"A Li","year":"2019","unstructured":"Li A, Vigers T, Pyle L et al (2019) Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros 18(1):144\u2013149. https:\/\/doi.org\/10.1016\/J.JCF.2018.07.010","journal-title":"J Cyst Fibros"},{"key":"6653_CR118","doi-asserted-by":"publisher","first-page":"100320","DOI":"10.1016\/J.JCTE.2023.100320","volume":"33","author":"F Lurquin","year":"2023","unstructured":"Lurquin F, Gohy S, Hermans MP, Preumont V (2023) Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes. J Clin Transl Endocrinol 33:100320. https:\/\/doi.org\/10.1016\/J.JCTE.2023.100320","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"6653_CR119","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1002\/PPUL.26562","volume":"58","author":"RS Ekblond","year":"2023","unstructured":"Ekblond RS, Nielsen BU, H\u00f8jte C et al (2023) Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment. Pediatr Pulmonol 58(9):2600\u20132609. https:\/\/doi.org\/10.1002\/PPUL.26562","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"6653_CR120","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMOA2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry PJ, Mall MA, \u00c1lvarez A et al (2021) Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes. N Engl J Med 385(9):815\u2013825. https:\/\/doi.org\/10.1056\/NEJMOA2100665","journal-title":"N Engl J Med"},{"issue":"19","key":"6653_CR121","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMOA1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med 381(19):1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMOA1908639","journal-title":"N Engl J Med"},{"issue":"21","key":"6653_CR122","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMOA1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar JL, Munck A, McKone EF et al (2017) Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377(21):2013\u20132023. https:\/\/doi.org\/10.1056\/NEJMOA1709846","journal-title":"N Engl J Med"},{"issue":"2","key":"6653_CR123","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/J.JCF.2021.09.001","volume":"21","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Marchetti P, Sawicki GS et al (2022) The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros 21(2):258\u2013263. https:\/\/doi.org\/10.1016\/J.JCF.2021.09.001","journal-title":"J Cyst Fibros"},{"key":"6653_CR124","doi-asserted-by":"publisher","first-page":"852551","DOI":"10.3389\/fped.2022.852551","volume":"10","author":"I Korten","year":"2022","unstructured":"Korten I, Kieninger E, Krueger L et al (2022) Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study. Front Pediatr 10:852551. https:\/\/doi.org\/10.3389\/fped.2022.852551","journal-title":"Front Pediatr"},{"issue":"4","key":"6653_CR125","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/J.JCF.2023.01.004","volume":"22","author":"C Steinack","year":"2023","unstructured":"Steinack C, Ernst M, Beuschlein F et al (2023) Improved glucose tolerance after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis. J Cyst Fibros 22(4):722\u2013729. https:\/\/doi.org\/10.1016\/J.JCF.2023.01.004","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6653_CR126","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.JCF.2023.11.005","volume":"23","author":"BU Nielsen","year":"2024","unstructured":"Nielsen BU, Olsen MF, Mabuza Mathiesen IH et al (2024) Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment. J Cyst Fibros 23(1):103\u2013108. https:\/\/doi.org\/10.1016\/J.JCF.2023.11.005","journal-title":"J Cyst Fibros"},{"issue":"2","key":"6653_CR127","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/J.JCF.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M (2022) Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 21(2):265\u2013271. https:\/\/doi.org\/10.1016\/J.JCF.2021.11.012","journal-title":"J Cyst Fibros"},{"issue":"11","key":"6653_CR128","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1210\/clinem\/dgaf099","volume":"110","author":"A Galderisi","year":"2025","unstructured":"Galderisi A, Weiss L, Besan\u00e7on A et al (2025) Effect of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. J Clin Endocrinol Metab 110(11):3220\u20133229. https:\/\/doi.org\/10.1210\/clinem\/dgaf099","journal-title":"J Clin Endocrinol Metab"},{"key":"6653_CR129","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/J.JCF.2025.03.1175","volume":"24","author":"D Appelt","year":"2025","unstructured":"Appelt D, Ruetz M, Fuchs T et al (2025) P289 effect of elexacaftor\/tezacaftor\/ivacaftor therapy on glycaemic status in CF: a single-centre retrospective study. J Cyst Fibros 24:S158\u2013S159. https:\/\/doi.org\/10.1016\/J.JCF.2025.03.1175","journal-title":"J Cyst Fibros"},{"key":"6653_CR130","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jcte.2022.100311","volume":"30","author":"CL Chan","year":"2022","unstructured":"Chan CL, Granados A, Moheet A et al (2022) Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis. J Clin Transl Endocrinol 30:100311. https:\/\/doi.org\/10.1016\/j.jcte.2022.100311","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"6653_CR131","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","volume":"110","author":"CL Chan","year":"2025","unstructured":"Chan CL, Shirley Bezerra M, Stefanovski D et al (2025) Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab 110(9):2674\u20132684. https:\/\/doi.org\/10.1210\/clinem\/dgae857","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6653_CR132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000530571","volume":"97","author":"J Park","year":"2024","unstructured":"Park J, Walsh A, Kerr S et al (2024) Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor. Horm Res Paediatr 97(1):94\u201398. https:\/\/doi.org\/10.1159\/000530571","journal-title":"Horm Res Paediatr"},{"key":"6653_CR133","doi-asserted-by":"publisher","first-page":"111839","DOI":"10.1016\/J.DIABRES.2024.111839","volume":"216","author":"I Aguilera Garc\u00eda","year":"2024","unstructured":"Aguilera Garc\u00eda I, Garc\u00eda Moreno RM, L\u00f3pez Plaza B et al (2024) Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pract 216:111839. https:\/\/doi.org\/10.1016\/J.DIABRES.2024.111839","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"6653_CR134","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/J.JCF.2025.03.007","volume":"24","author":"C Wood","year":"2025","unstructured":"Wood C, Moheet A, Vigers T et al (2025) Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros 24(4):755\u2013758. https:\/\/doi.org\/10.1016\/J.JCF.2025.03.007","journal-title":"J Cyst Fibros"},{"issue":"10","key":"6653_CR135","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/LIFE14101309\/S1","volume":"14","author":"M Bassi","year":"2024","unstructured":"Bassi M, Strati MF, Spiandorello G et al (2024) One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study. Life 14(10):1309. https:\/\/doi.org\/10.3390\/LIFE14101309\/S1","journal-title":"Life"},{"key":"6653_CR136","doi-asserted-by":"publisher","first-page":"100307","DOI":"10.1016\/J.JCTE.2022.100307","volume":"30","author":"H Crow","year":"2022","unstructured":"Crow H, Bengtson C, Shi X, Graves L, Anabtawi A (2022) CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy. J Clin Transl Endocrinol 30:100307. https:\/\/doi.org\/10.1016\/J.JCTE.2022.100307","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"6653_CR137","doi-asserted-by":"publisher","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","volume":"49","author":"V Grancini","year":"2023","unstructured":"Grancini V, Gramegna A, Zazzeron L et al (2023) Effects of elexacaftor\/tezacaftor\/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis related diabetes. Diabetes Metab 49(5):101466. https:\/\/doi.org\/10.1016\/j.diabet.2023.101466","journal-title":"Diabetes Metab"},{"key":"6653_CR138","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/J.JCTE.2024.100332","volume":"35","author":"M Amini","year":"2024","unstructured":"Amini M, Yu K, Liebich J et al (2024) The changing landscape of treatment for cystic fibrosis related diabetes. J Clin Transl Endocrinol 35:100332. https:\/\/doi.org\/10.1016\/J.JCTE.2024.100332","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"6653_CR139","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/PPUL.26388","volume":"58","author":"A Granados","year":"2023","unstructured":"Granados A, Chan CL, Moheet A, Vigers T, Arbel\u00e1ez AM, Larson Ode K (2023) The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol 58(6):1805\u20131811. https:\/\/doi.org\/10.1002\/PPUL.26388","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"6653_CR140","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F et al (2025) Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med 13(3):256\u2013271. https:\/\/doi.org\/10.1016\/S2213-2600(24)00411-9","journal-title":"Lancet Respir Med"},{"issue":"1","key":"6653_CR141","doi-asserted-by":"publisher","first-page":"8617","DOI":"10.1038\/S41598-023-35416-W","volume":"13","author":"P Suppakitjanusant","year":"2023","unstructured":"Suppakitjanusant P, Kasemkosin N, Sivapiromrat AK et al (2023) Predicting glycemic control status and high blood glucose levels through voice characteristic analysis in patients with cystic fibrosis-related diabetes (CFRD). Sci Rep 13(1):8617. https:\/\/doi.org\/10.1038\/S41598-023-35416-W","journal-title":"Sci Rep"},{"issue":"5","key":"6653_CR142","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","volume":"21","author":"S Szentpetery","year":"2022","unstructured":"Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK (2022) Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros 21(5):777\u2013783. https:\/\/doi.org\/10.1016\/j.jcf.2022.03.010","journal-title":"J Cyst Fibros"},{"issue":"7","key":"6653_CR143","doi-asserted-by":"publisher","first-page":"E41697","DOI":"10.7759\/cureus.41697","volume":"15","author":"M Salazar-Barragan","year":"2023","unstructured":"Salazar-Barragan M, Taub DR (2023) The effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review. Cureus 15(7):E41697. https:\/\/doi.org\/10.7759\/cureus.41697","journal-title":"Cureus"},{"issue":"3","key":"6653_CR144","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/J.JCF.2023.01.008","volume":"22","author":"NRA Bruijn","year":"2023","unstructured":"Bruijn NRA, Wagenmakers MAEM, van Hoek M, Apers JA, van der Eerden MM, \u00d6zcan B (2023) Bariatric surgery in a patient with cystic fibrosis and diabetes: a case report. J Cyst Fibros 22(3):577\u2013579. https:\/\/doi.org\/10.1016\/J.JCF.2023.01.008","journal-title":"J Cyst Fibros"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06653-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:51:55Z","timestamp":1772553115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06653-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":144,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["6653"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06653-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GYL has received research funding to her institution from Roche Diagnostics, Alberta Lung, the University Hospital Foundation, Long COVID Web and the Canadian Institutes of Health Research (CIHR).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"GYL has received honoraria for educational activities from Boehringer Ingelheim, Alberta Lung and Canadian Thoracic Society\/Respiplus. However, none of these competing interests are related to the topic of this review. HS declares that there are no relationships or activities that might bias, or be perceived to bias, her work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"GYL was responsible for conceptualisation, development of methodology, supervision and manuscript writing. HS was responsible for drafting the manuscript, manuscript editing and review. Both authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}